Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.76 USD | -1.05% |
|
-6.47% | -20.00% |
06-24 | Transcript : Aprea Therapeutics, Inc. - Special Call | |
06-17 | Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.00% | 20.63M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- APRE Stock
- News Aprea Therapeutics, Inc.
- Transcript : Aprea Therapeutics, Inc. - Special Call